



PHYSICAL CHEMISTRY 2006

Proceedings

*of the 8th International Conference
on Fundamental and Applied Aspects of
Physical Chemistry*

September 26-29,
Belgrade, Serbia

ISBN 86-82139-26-X
Title: Physical Chemistry 2006. (Proceedings)
Editors Prof. dr A. Antić-Jovanović
Published by: The Society of Physical Chemists of Serbia, Studentski trg 12-16, P.O.Box 137, 11001 Belgrade, Serbia
Publisher: Society of Physical Chemists of Serbia
For publisher: Prof. dr S. Anić, president of the Society of Physical Chemists of Serbia
Printed by: "Jovan" Printing and Published Comp;
250 Copies; Number of Pages: x + 442; Format B5;
Printing finished in September 2006.
Text and Layout: Aleksandar Nikolić
250 – copy printing

**^{99m}Tc -HEXAKIS-(2-METOXY-ISOBUTYL-ISONITRILE)
(^{99m}Tc -MIBI) A NEW MYOCARDIAL IMAGING AGENT:
SYNTHESIS OF MIBI, OPTIMISING CONDITIONS FOR
RADIOLABELLING WITH ^{99m}Tc AT HIGH RADIOCHEMICAL
PURITY AND *IN VIVO* BEHAVIOR**

D. Đokić¹, D. Janković¹, Lj. Stamenković¹, N. Nikolić¹,
M. D. Mirković¹ and I. Pirmettis²

¹Laboratory of Radioisotopes, Institute of Nuclear Sciences «Vinča»
POBox 522, Belgrade, Serbia

² Institute of Radioisotopes and Radiodiagnostic Products, NCSR “Demokritos”
POB 60228, 15310 Agia Paraskevi, Athens, Greece

Abstract

^{99m}Tc -MIBI is a promising radiopharmaceutical for myocardial perfusion imaging agent, but it has also shown good results in identifying several types of tumors, such as breast, lung and thyroid cancers. It is a lipophilic, cationic technetium (I) complex. In this paper a complete study on the synthesis of 2-methoxy-isobutyl-isonitrile (MIBI) as well as a formulation of a lyophilized kit for labeling with ^{99m}Tc is presented. Investigation on effective factors as well as finding out the optimum parameters to obtain the highest labelling efficiency and radiochemical purity of ^{99m}Tc -MIBI complex were performed. The radiochemical purity of the labelled preparation was high (>95%). Biodistribution study performed in health male Wistar rats showed satisfactory biokinetics results. ^{99m}Tc -MIBI was accumulated in sufficient amount into the heart tissue for myocardial perfusion imaging. MIBI in kit formulation was found to be stable and also safe for administration.

Introduction

[Hexakis-(2-methoxy-isobutyl) isonitriletechnetium (I)]⁺, developed as potential myocardial imaging agent, is a member of the class of lipophilic hexakisisonitriletechnetium (I) cationic complexes, [Tc(CNR)]⁺, where R is the alkyl group such as methyl, ethyl, n-propyl, tertiary butyl or methoxy isobutyl substituents [1]. It is a +1 complex, Tc in the center is symmetrically bounded to six monodentate CNR ligands resulting in stable cationic complexes. Isonitriles stabilize Tc(I) by their p-acceptor properties. These compounds don't undergo the *in vivo* reductive mechanisms in the human heart owing to the low oxidation state of technetium. An investigation into the mechanism of uptake has led to the belief that cations such as [Tc(MIBI)₆]⁺ accumulate *via* a diffusion mechanism and electrostatic binding due to a high mitochondrial membrane potential. The lipophilicity of the complex is known to be important for uptake into the heart. Tc(I) oxidation state is accessible directly from pertechnetate ($^{99m}\text{TcO}_4^-$) as the complex is obtained by the reaction of $^{99m}\text{TcO}_4^-$ and tetra-(2-methoxy-isobutyl-isonitril) copper tetrafluoroborate [Cu(MIBI)₄] BF₄ and in presence of SnCl₂ as reducing agent [2, 3].

Material and Methods

The synthesis of MIBI and chelate $[\text{Cu}(\text{MIBI})_4]\text{BF}_4$ was based on a method previously reported [4], with certain modifications. The compounds were characterized by elemental analysis, IR and $^1\text{H-NMR}$ spectroscopy. After optimization of reaction parameters, MIBI was prepared as a freeze dried kit. The labelling was performed by adding of 1-5 ml of $^{99\text{m}}\text{TcO}_4^-$ ($^{98}\text{Mo}/^{99\text{m}}\text{Tc}$ -generator, Vinča) and heating for fifteen minutes in boiling water bath. Analysis of the product included the radiochemical quality control, determination of pharmacokinetical parameters as well as biodistribution study. Radiochemical purity was assayed by Whatman 3MM paper chromatography and ITLC-SG in ethylacetate and two solvent system (acetone/saline) respectively. The standard trichloroacetic acid (TCA) precipitation method was used for determining the binding of $^{99\text{m}}\text{Tc-MIBI}$ to protein. All lipophilicity measurements were done by solvent extraction method with n-octanol. The biodistribution studies were carried out using health male Wistar rats (n=4-6). Animals were sacrificed at different times and samples of tissues or organs of interest were removed for assay of radioactivity.

Results and Discussion

The different concentrations and molar ratios of $[\text{Cu}(\text{MIBI})_4]\text{BF}_4$ and $\text{SnCl}_2 \times 2\text{H}_2\text{O}$ as well as the volume of $^{99\text{m}}\text{TcO}_4^-$ elute used for labeling, had a great influence on the labelling yield and stability of the preparation (Table 1 and 2). The optimum quantity of Sn(II) added into kit formulation was investigated by preparing MIBI kits containing various concentrations of Sn(II), while amounts of MIBI and others components were kept constant. The experimental results confirmed that concentration ratio: $[\text{Sn}]/[\text{MIBI}]=1/13.5$ and the presence of 0.025 mg/ml of $\text{SnCl}_2 \times 2\text{H}_2\text{O}$ in freeze-dried kit, gave satisfactory biological behavior in rats.

Table 1. The effect of Sn(II) concentration on radiochemical purity results of $^{99\text{m}}\text{Tc-MIBI}$ (Whatman 3MM, Ethyl Acetate), $V_{\text{TcO}_4^-}=3$ ml

Time after labelling	30 (min)		300 (min)	
	TcO_2^+ TcO_4^- Rf=0.0	Tc-MIBI Rf=0.6	TcO_2^+ TcO_4^- Rf=0.0	Tc-MIBI Rf=0.6
[Sn(II)] mg/ml				
0.25	4.5±0.2	95.5±0.2	5.1±0.5	94.9±0.5
0.025	2.2±0.2	98.0±0.9	2.4±0.4	97.6±0.8

Table 2. The effect of $^{99\text{m}}\text{TcO}_4^-$ volume on radiochemical purity results of $^{99\text{m}}\text{Tc-MIBI}$

$V_{\text{TcO}_4^-}$ (ml)	Labelling Yield (%)	
	TcO_2^+ TcO_4^-	Tc-MIBI
1	9.4±0.7	90.6±0.9
2	6.1±0.3	93.9±0.8
3	2.2±0.6	97.8±0.6
4	2.8±0.8	97.2±0.8
5	3.3±0.9	96.7±0.3

Reconstitution of the kit with 1-5 ml of $^{99\text{m}}\text{TcO}_4^-$ showed high radiochemical purity and stability. The freeze dried kit for $^{99\text{m}}\text{Tc-MIBI}$ is stable at least 5 h after labelling. The effect of heating on the radiochemical yield was tested. $^{99\text{m}}\text{Tc-MIBI}$ was pre-

pared with and without heating. Without heating much lower radiochemical purity results were obtained. The percentage of ^{99m}Tc -MIBI bound to protein was very high (94.8%). N-octanol-buffer distribution pH profiles showed that the distribution coefficient was around 0.5 and independent on pH. From values of radioactivity measured per organ of interest, the percentages of radioactivity related to administered dose were determined. *In vitro* studies showed the significant heart uptake and low blood and liver uptake (Table 3). The effect of Sn(II) concentration on *in vivo* behavior was remarkable.

Table 3. Effect of [Sn (II)] on biodistribution studies results of ^{99m}Tc -MIBI on Wistar rats, % Administered dose \pm SD per g (%/g), ($V_{^{99m}\text{TcO}_4^-}$ =5 ml)

Organ	[Sn(II)]= 0.025 mg/ml	[Sn(II)]= 0.25 mg/ml
Heart	3.12 \pm 0.38	3.77 \pm 0.21
Blood	0.02 \pm 0.01	0.03 \pm 0.01
Lungs	0.33 \pm 0.05	0.67 \pm 0.10
Liver	0.84 \pm 0.01	1.03 \pm 0.31
Spleen	0.46 \pm 0.12	0.32 \pm 0.12
Kidneys	2.17 \pm 0.30	1.75 \pm 0.20
Stomach	0.73 \pm 0.01	0.45 \pm 0.17
Intestine	2.20 \pm 0.12	1.12 \pm 0.18
Heart/Blood	198.89	132.59
Heart/Lungs	9.414	5.65
Heart/Liver	3.71	3.67

Conclusion

MIBI was prepared as freeze dried form. Reconstitution of the kit performed with 2-5 ml of $^{99m}\text{TcO}_4^-$ showed high radiochemical purity. A satisfactory biodistribution of ^{99m}Tc -MIBI behaviour in healthy test animals was obtained. Additional clinical studies could confirm the promising characteristic of ^{99m}Tc -MIBI.

References

- [1] L.I. Delmon-Moingeon; D. Piwnica-Worms, D.A. Van den Abbeele, Cancer Research, 1990, **50**(7), 2198-2202.
- [2] Technetium Tc 99m Sestamibi Injection, Official Monographs, USP XXV, 2002, USP-NF, 1601-1602.
- [3] M. Kosinski, C. Terwinghe, J.Cleynhens, In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine, 6, M. Nicolini, U. Mazzi. ed. SG Editoriali: Italy, 2002, 551-553.
- [4] G. Subramanian, IAEA, TECDOC-532, 1989